NKX101 – VJRegenMed

Allogeneic NKX101 in liver cancer

Simon Ng — Tue, 26 Oct 2021 09:52:59 +0000

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, discusses NKX101 in solid tumor indications. NKX101, an allogeneic NKG2D receptor chimeric antigen receptor (CAR) natural killer (NK) cell therapy, is currently being assessed in patients with relapsed/refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) in a Phase I trial (NCT04623944). In addition to AML and MDS, NKX101 use is being extended to liver localized tumors including hepatocellular carcinoma (HCC) and metastatic colorectal cancer. Transarterial delivery will enable successful trafficking of the cell therapy to the tumor by concentrating NKX101 in the tumor. This interview took place at Meeting on the Mesa 2021.

NKX019 in B-cell malignancies

Simon Ng — Tue, 26 Oct 2021 09:52:58 +0000

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, describes the development of NKX019, an off-the-shelf CD19-directed chimeric antigen receptor (CAR) natural killer (NK) cell therapy in patients with B-cell malignancies including lymphomas and leukemias. NKX019 aims to address current challenges CAR-T cell therapies face by improving safety and patient accessibility whilst maintaining efficacy. This interview took place at Meeting on the Mesa 2021.

Allogenic NKX101 in r/r AML

admin_vjr_user — Tue, 22 Jun 2021 13:58:16 +0000

James Trager, PhD, NKarta Therapeutics, South San Francisco, CA describes the ongoing Phase I clinical trial (NCT04623944) of NKX101, an allogeneic NKG2D receptor chimeric antigen receptor (CAR) natural killer (NK) cell therapy, in patients with relapsed/refractory acute myeloid leukemia (AML). The study aims to examine NKX101 monotherapy derived from both human leukocyte antigen (HLA)-matched and unmatched donors in order to investigate the role of HLA matching and the potential of developing a broad, non-matched off-the-shelf program that enables the selection of donors with enhanced NK cell activity and manufacturability. This interview took place during the CAR-TCR Summit Europe 2021.